NVO Novo Nordisk A/S

NYSE
$39.43

Novo Nordisk A/S (NVO) is expected to report earnings on February 3, 2027, before the market open. The consensus earnings estimate is $0.68 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -7.1% since its last earnings release on November 4, 2026.

Novo Nordisk A/S Missed Expectations, Raises Guidance
Wednesday, November 4, 2026 · 1:30 AM ET
Earnings Date
4th Quarter, Dec 2026
Feb 3
Wednesday · 1:30 AM ET
Earnings Whisper
-
vs $0.68
Rev est $11.82B
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $41.15

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Novo Nordisk A/S

Novo-Nordisk A/S is a healthcare company that is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company has two business segments: diabetes care and biopharmaceuticals.

Sector

Healthcare

Industry

Drug Manufacturers / Major

Held By 1 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.